Immunization News and Research

RSS

‘Press 1 for English’: Vaccination sign-ups prove daunting for speakers of other languages

In late February, a week after Virginia launched a centralized website and call center for covid-19 vaccine preregistration, Zowee Aquino alerted the state to a glitch that could prove fatal for non-English speakers trying to secure a shot.

23 Mar 2021

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

To understand the ability of SARS-CoV-2 vaccine-elicited antibodies to neutralize and protect against emerging variants (that are pathogenic) and other sarbecoviruses, a large team of researchers studied immunity by receptor-binding domain nanoparticle vaccines. They showed that a clinical-stage multivalent SARS-CoV-2 receptor-binding domain nanoparticle vaccine (SARS-CoV-2 RBD-NP) protected mice from the SARS-CoV-2-induced disease.

22 Mar 2021

Vaccine passports raise questions of equity, security, and privacy

Vaccine passports raise questions of equity, security, privacy, argues Crispin Maslog. China, where the COVID-19 pandemic began a long year ago, has now become the first country in the world to issue a vaccine passport to promote world economic recovery and facilitate cross-border travel.

22 Mar 2021

The case for donating US Covid vaccines overseas

A Senate committee grilled federal officials about the shortage of vaccines to protect Americans against a pandemic virus. Two months later, the U.S. public had lost interest in the virus, and millions of vaccines were sitting in warehouses — although poor countries still needed them.

19 Mar 2021

Mass vaccination needed to protect against future resurgences of COVID-19

The first long-term seroprevalence study of residents in Wuhan, China, has found that 6.9% of people in the city had antibodies against COVID-19 in April 2020, and 82% of these people had an asymptomatic infection.

19 Mar 2021

Can vaccine evading SARS-CoV-2 variants be restricted by prioritized vaccine rollout?

A new study discusses the question of how vaccine priority is affected by the possibility of vaccine escape.

18 Mar 2021

Arrayjet plays a key role in the development of anti-malarial vaccination

The quest to develop effective malarial vaccines is now a step closer with Scottish bio-printer manufacturer Arrayjet, selected to work with a Kenyan-based medical research group to assist ongoing R&D trials that could lead to a vaccination immunization program to tackle malaria in less than two years.

17 Mar 2021

Janssen’s vaccine added to list of safe, effective tools against COVID-19

The World Health Organization (WHO) today listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced yesterday.

16 Mar 2021

New strategy may change the course of evolving COVID-19 pandemic

Launched in April 2020 by the World Health Organization (WHO), European Commission, France and The Bill & Melinda Gates Foundation, the ACT Accelerator is a partnership of leading public health agencies with equity at its heart.

16 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

New vaccination method aims at comprehensive protection against all known influenza mutations

One shot, protected forever: This would be a dream come true regarding influenza vaccinations. So far, vaccination against influenza did not provide a lasting protection.

13 Mar 2021

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Researchers based in India have demonstrated that horses inoculated with an inactivated dosage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to produce large amounts of strong antibodies that can neutralize multiple variants

12 Mar 2021

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

A group of researchers based at the Papa Giovanni XXIII hospital in Italy have submitted evidence to suggest that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may adequately benefit from a single dose of mRNA vaccine, rather than requiring the current two-vaccine regimen.

12 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19).

11 Mar 2021

One in four people could face some degree of hearing loss by 2050, WHO report warns

One in four people across the world — nearly 2.5 billion — could face some degree of hearing loss by 2050 with at least 700 million requiring access to treatment and rehabilitation, a WHO report warns.

11 Mar 2021

Nanobody works against all SARS-CoV-2 variants of concern in animal model

Researchers based in Belgium have developed a new antibody drug that is highly successful at neutralizing coronavirus disease 2019 (COVID-19) in Syrian hamsters. The new biologic was administered to the rodents and was found to be equally successful at neutralizing the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain, and also the new mutant variants, such as the South African and UK strains.

11 Mar 2021

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues, many countries have rolled out vaccines against the virus. In an encouraging preprint research paper posted to the medRxiv* server, scientists report on the vaccine efficacy in the Danish vaccination program.

10 Mar 2021

Mass immunization to stop Ebola outbreak in Guinea

As the first shipment of COVID-19 vaccines arrived in Africa this week, another vaccine was being rolled out in Guinea, in a bid to stop a fresh outbreak of Ebola in its tracks.

10 Mar 2021

Immunization News and Research

‘Press 1 for English’: Vaccination sign-ups prove daunting for speakers of other languages

Could nanoparticle vaccines offer broad protection against sarbecoviruses?

Vaccine passports raise questions of equity, security, and privacy

The case for donating US Covid vaccines overseas

Mass vaccination needed to protect against future resurgences of COVID-19

Can vaccine evading SARS-CoV-2 variants be restricted by prioritized vaccine rollout?

Arrayjet plays a key role in the development of anti-malarial vaccination

Janssen’s vaccine added to list of safe, effective tools against COVID-19

New strategy may change the course of evolving COVID-19 pandemic

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

Which biomarkers can help predict severe COVID-19?

New vaccination method aims at comprehensive protection against all known influenza mutations

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

One in four people could face some degree of hearing loss by 2050, WHO report warns

Nanobody works against all SARS-CoV-2 variants of concern in animal model

Danish study on the efficacy of Pfizer/BioNTech SARS-CoV-2 vaccine after first and second dose

Mass immunization to stop Ebola outbreak in Guinea

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News